查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863246

抗菌素抗藥性監測市場：按產品、技術、應用和最終用戶分類－2025-2032年全球預測

Antimicrobial Resistance Surveillance Market by Offering, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗菌素抗藥性監測市場將成長至 100.1 億美元，複合年成長率為 6.70%。

主要市場統計數據
基準年 2024 59.6億美元
預計年份：2025年 63.6億美元
預測年份：2032年 100.1億美元
複合年成長率 (%) 6.70%

引人入勝的引言將抗菌素抗藥性監測定位為臨床、技術和系統層面的緊迫優先事項，需要綜合診斷和數據。

抗菌藥物抗藥性監測處於臨床緊迫性、技術進步和公共衛生策略的交匯點，需要協調一致的實施，以清晰闡明挑戰和不斷變化的應對情況。本初步評估總結了協調監測對於維持治療效果至關重要的原因。細菌病原體抗藥性的不斷增強正在重塑診斷重點，加速了對快速表現型和基因型檢測的需求，並迫使檢查室和衛生系統重新思考如何在其網路中收集、分析和共用數據。除了臨床意義之外，監測系統在食品安全、環境監測和流行病學情報方面也日益發揮核心作用，擴大了相關人員的範圍，並強化了對可互通數據標準和安全資訊交流的需求。

對重塑全球抗菌素抗藥性監測系統的關鍵技術、操作和政策主導變革進行了深入分析。

抗菌藥物抗藥性監測格局正經歷著一場變革性的轉變，其促進因素包括技術的成熟、政策的調整以及相關人員期望的轉變；本節將詳細闡述這些關鍵的變革促進因素。快速表現型檢測和高效能定序技術的進步縮短了從檢體到可操作結果的時間，從而能夠更精準地管理抗菌藥物，並更早發現新出現的抗藥性模式。同時，數位健康平台和檢查室資訊系統促進了臨床、公共衛生、食品安全和環境等領域之間更豐富的數據協作，強化了從孤立的檢測事件向持續監測的轉變。這些技術變革與日益嚴格的監管以及對資料透明度不斷成長的期望相輔相成，促使各組織加強檢驗流程並投資於互通性標準。

全面評估近期關稅變化對整個監測生態系統採購趨勢、供應彈性策略和營運計畫的影響

2025年生效的一系列關稅措施的累積效應，為診斷試劑、試劑和檢測設備的採購計算引入了新的變數。本節不進行數值預測，而是著重分析其實際影響。更高的進口關稅和相關的貿易執法行動，加劇了依賴跨境供應鏈獲取關鍵耗材和複雜設備的實驗室和醫療系統的成本壓力。為此，採購團隊和供應機構日益重視採購多元化、本地製造夥伴關係以及庫存最佳化策略，旨在減少對單一國家的依賴。同時，這些貿易變化也提升了基於服務的供應模式和試劑租賃項目的吸引力，這些模式和項目能夠緩解設施資本支出的波動。

詳細的細分分析揭示了產品供應、技術、應用領域和最終用戶需求如何共同決定監控優先順序和採購行為。

關鍵細分市場分析揭示了產品技術、應用和最終用戶等不同維度如何交織影響抗菌藥物抗藥性監測的採購優先順序、工作流程和投資選擇。市場分析依產品類型分類，涵蓋耗材和試劑、儀器、服務和軟體。耗材和試劑部分重點在於抗生素檢測板、培養基和PCR試劑盒，每種產品在監測管道中都發揮特定作用，並具有各自獨特的供應和檢驗要求。儀器涵蓋多種平台，從手動抗菌藥物敏感性試驗（AST）台到全自動系統和質譜儀。同時，服務和軟體支援遠端數據分析、品質保證以及將監測結果整合到臨床決策支援系統中。

針對特定區域的分析揭示了地理位置相關的基礎設施、採購結構和製造能力如何影響監控設定和供應商策略。

區域趨勢對監測重點、供應鏈以及診斷技術的應用軌跡有顯著影響。本節將綜合分析關鍵區域的具體背景及其戰略意義。在美洲，完善的公共衛生基礎設施和集中式參考實驗室為定序和自動化藥敏試驗的高普及率提供了支持，而採購週期和報銷機制則影響著供應商的合作模式。此外，北美和南美的區域互聯互通促進了疫情監測和數據共用的合作網路，這反過來又影響著供應商如何定位其整合硬體/軟體解決方案和服務產品。

本次演講將為企業提供可操作的見解，幫助其利用整合平台、供應鏈彈性和夥伴關係模式，重新定義監控解決方案的競爭優勢。

在抗菌素抗藥性監測領域營運的公司正從單一產品策略轉向整合硬體、試劑、資訊科學和服務的一體化解決方案。本節將重點放在定義其競爭地位的策略舉措。領先的診斷和生命科學供應商正在投資開發支援表現型和基因型檢測管道的模組化平台，使客戶能夠簡化工作流程並降低複雜性。同時，專業試劑公司正在開發檢驗的檢測組合，以簡化監管合規性並加速在各種實驗室環境中的部署。隨著互通性和數據分析成為尋求端到端監測能力的客戶的關鍵差異化因素，儀器製造商和軟體開發商之間的策略聯盟正變得越來越普遍。

為高階主管和職能領導者提供切實可行的、影響深遠的建議，以增強其營運中監測系統的韌性、互通性和臨床效用。

產業領導者必須採取重點突出、切實可行的策略，將監測情報轉化為營運韌性和臨床影響力。本節概述了針對高階經營團隊和職能領導者的量身定做、影響深遠的建議。首先，優先考慮供應商多元化和合約機制，以確保關鍵耗材和備件的供應，同時避免依賴單一供應商。發展區域供應商關係並採用靈活的採購模式將顯著降低營運風險。其次，投資可互通的資料架構和檢驗的分析工具，將檢查室數據與臨床和公共衛生系統連接起來。互通性能夠實現跨組織邊界的快速檢測、集中監測和協調響應。第三，加快有針對性的自動化和數位化工作流程，以減少重複性高技能任務，同時提高可重複性和效率。透過自動化和能力建構相結合的方式，保持深厚的人才儲備。

我們採用透明且可複製的調查方法，結合相關人員訪談、文獻綜合、專家檢驗和跨區域比較，得出可靠的結論。

本分析的調查方法融合了定性和定量方法，以確保得出可靠的實證結論，同時保持資料來源和檢驗過程的透明度。主要研究包括對檢查室主任、採購負責人、臨床微生物學家、公共衛生負責人和技術供應商進行結構化訪談，以收集有關營運挑戰、採購行為和技術應用障礙的第一手資料。此外，還對同行評審文獻、監管指南、技術白皮書和已發表的臨床檢驗研究進行了全面審查，這些研究詳細介紹了檢測性能特徵和工作流程整合方面的考慮因素。

關鍵整合強調在技術、互通性和供應韌性方面的協調投資，以保障治療效果和公共衛生結果。

總之，抗菌素抗藥性監測正從單一檢查室的活動轉變為涵蓋臨床護理、公共衛生、食品安全和環境監測的協作式、數據驅動型系統。快速表現型分析、定序和數位分析等技術的進步使得監測訊號更加豐富，介入措施也更加迅速，但要充分發揮這些潛力，需要對互通性、人員能力和供應鏈韌性進行有意識的投資。政策變化、採購壓力和不斷演變的商業模式的綜合影響，迫使各組織在短期營運連續性和長期能力建設之間尋求平衡。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新興的基於 CRISPR 的新型診斷工具可用於臨床環境中快速檢測抗菌藥物抗藥性
  • 將人工智慧和機器學習技術整合到監測網路中，用於預測抗菌素抗藥性建模
  • 利用全基因組定序闡明社區中多重抗藥性細菌的傳播途徑
  • 擴大社區污水監測計劃，以識別都市區新出現的抗藥性基因
  • 監管機構推動建立標準化的全球報告框架，以協調抗菌素抗藥性數據共用通訊協定
  • 在資源匱乏的環境中推廣照護現場分子檢測，以實現分散式抗菌藥物抗藥性檢測。
  • 製藥公司與學術機構進行策略合作，加速發現針對抗藥性病原體的新型抗生素
  • 實施「同一健康」舉措，整合人類、動物和環境抗菌素抗藥性監測數據，以進行全面的風險評估

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按產品/服務分類的抗菌素抗藥性監測市場

  • 耗材和試劑
    • 抗生素檢測
    • 培養基
    • PCR試劑盒
  • 裝置
  • 服務
  • 軟體

9. 按技術分類的抗菌素抗藥性監測市場

  • 自動化抗生素敏感性測試系統
  • 手動抗生素敏感性試驗
  • 質譜分析
  • 下一代定序
  • 即時PCR

第10章：抗菌素抗藥性監測市場（按應用領域分類）

  • 環境監測
  • 流行病學監測
  • 食品安全檢查
  • 感染控制

第11章 依最終用戶分類的抗菌素抗藥性監測市場

  • 學術研究機構
  • 臨床檢查室
  • 醫院檢查室
  • 製藥和生物技術公司
  • 參考檢查室

12. 按地區分類的抗菌素抗藥性監測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的抗菌素抗藥性監測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國抗菌素抗藥性監測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd
    • Becton, Dickinson and Company
    • bioMerieux SA
    • QIAGEN NV
    • Illumina, Inc.
    • bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Merck KGaA
    • Accelerate Diagnostics, Inc.
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market is projected to grow by USD 10.01 billion at a CAGR of 6.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.96 billion
Estimated Year [2025] USD 6.36 billion
Forecast Year [2032] USD 10.01 billion
CAGR (%) 6.70%

A compelling introduction that frames antimicrobial resistance surveillance as an urgent clinical, technological, and systems-level priority requiring integrated diagnostics and data

Antimicrobial resistance surveillance sits at the intersection of clinical urgency, technological advancement, and public health strategy, requiring a coherent introduction that frames the challenge and the evolving response landscape. The opening assessment synthesizes why coordinated surveillance is foundational to preserving therapeutic efficacy: rising resistance profiles among bacterial pathogens are reshaping diagnostic priorities, accelerating demand for rapid phenotypic and genotypic testing, and forcing laboratories and health systems to reconsider how data is collected, analyzed, and shared across networks. In addition to clinical implications, surveillance systems are increasingly central to food safety, environmental monitoring, and epidemiological intelligence, thereby broadening the stakeholder base and amplifying requirements for interoperable data standards and secure information exchange.

Moreover, the contemporary introduction emphasizes the convergence of instrumentation, consumables, informatics, and services as integral components of an effective surveillance ecosystem. Diagnostic manufacturers, reagent suppliers, software developers, and service providers must coordinate to deliver integrated solutions that support real-time decision making. This introduction also acknowledges the operational pressures felt by laboratories, including workforce constraints, supply chain volatility, and regulatory requirements, while underscoring how investments in automation, sequencing, and analytics can enhance throughput and generate higher-fidelity surveillance signals. Ultimately, the introduction sets the stage for a report that balances technical detail with strategic implications, positioning surveillance as both a clinical necessity and a systems-level capability that demands sustained investment and cross-sector collaboration

Insightful analysis of the major technological, operational, and policy-driven shifts reshaping antimicrobial resistance surveillance systems worldwide

The landscape for antimicrobial resistance surveillance is undergoing transformative shifts driven by technological maturation, policy momentum, and changing stakeholder expectations, and this section details the principal vectors of change. Advances in rapid phenotypic testing and high-throughput sequencing have shortened the time from sample to actionable insight, enabling more precise antimicrobial stewardship and earlier detection of emerging resistance patterns. Concurrently, digital health platforms and laboratory information systems are enabling richer data linkages across clinical, public health, food safety, and environmental domains, reinforcing the shift from isolated testing events to continuous surveillance streams. These technological changes are complemented by growing regulatory scrutiny and heightened expectations for data transparency, prompting organizations to strengthen validation pathways and invest in interoperability standards.

In parallel, an operational recalibration is occurring across supply chains and service models. Laboratories are balancing in-house capability expansion with outsourced testing partnerships, while manufacturers are rethinking production flexibility and distribution strategies to mitigate supply disruptions. Workforce dynamics are also shifting: skilled laboratory professionals face increased demand, and organizations are deploying automation and remote-support models to preserve capacity. Taken together, these trends are not simply incremental; they are altering how surveillance programs are designed, funded, and operated. Decision-makers must therefore adapt governance models, invest in resilient supply relationships, and prioritize technologies that integrate seamlessly into existing clinical and public health workflows

Comprehensive evaluation of how recent tariff shifts are altering procurement dynamics, supply resilience strategies, and operational planning across surveillance ecosystems

The cumulative effect of tariff measures enacted in 2025 has introduced new variables into the procurement calculus for diagnostics, reagents, and laboratory instrumentation, and this section traces the practical implications without presuming numerical projections. Higher import duties and related trade policy measures have intensified the cost pressures on laboratories and health systems that rely on cross-border supply chains for critical consumables and complex instruments. In response, procurement teams and supplier organizations have increasingly prioritized diversification of sourcing, localized manufacturing partnerships, and inventory optimization strategies aimed at reducing single-country dependency. At the same time, these trade shifts have reinforced the attractiveness of service-based delivery models and reagent rental programs that can buffer facilities from capital expenditure volatility.

Regulatory and compliance burdens have also been affected, as increased tariffs may trigger adjustments in supplier contracts, customs processes, and lead-time expectations, necessitating more rigorous supplier performance monitoring and contractual protections. For manufacturers, the tariff environment has accelerated strategic decisions around regional manufacturing footprints and tariff engineering to preserve competitiveness. Health systems and reference labs are consequently adapting by strengthening demand forecasting, expanding collaborative purchasing consortia, and exploring homologation strategies to qualify alternative suppliers more rapidly. Importantly, these responses underscore a broader trend toward supply chain resilience and operational flexibility, where procurement agility and supplier transparency become as critical as product performance in sustaining effective antimicrobial resistance surveillance

In-depth segmentation insights revealing how product offerings, technologies, applications, and end-user needs collectively determine surveillance priorities and procurement behaviors

Key segmentation insights illuminate how distinct product, technology, application, and end-user dimensions intersect to shape procurement priorities, operational workflows, and investment choices within antimicrobial resistance surveillance. When examining the market by offering, the landscape spans consumables and reagents, instruments, services, and software; within consumables and reagents, attention centers on antibiotic panels, culture media, and PCR kits, each of which plays a specific role in surveillance pathways and has discrete supply and validation requirements. Instruments encompass a range of platforms from manual AST benches to fully automated systems and mass spec analyzers, while services and software enable remote data interpretation, quality assurance, and the integration of surveillance outputs into clinical decision support systems.

From a technology perspective, automated antimicrobial susceptibility testing systems, manual AST methods, mass spectrometry platforms, next-generation sequencing workflows, and real-time PCR assays present distinct trade-offs in turnaround time, sensitivity, and operational complexity. Applications drive adoption priorities differently: environmental monitoring emphasizes robust sample handling and throughput, epidemiological surveillance prioritizes data continuity and lineage tracing, food safety testing requires stringent traceability, and infection control focuses on rapid detection at the point of care or within hospital laboratories. End users further shape procurement and deployment models: academic and research institutes value configurability and depth of data, clinical laboratories and hospital laboratories prioritize throughput and regulatory compliance, pharmaceutical and biotechnology companies require stringent controls for development programs, and reference laboratories demand scalable, high-volume platforms. Understanding these segmentation dynamics is essential for aligning product development, commercialization strategies, and service models with the real-world needs of diverse stakeholders

Targeted regional analysis that clarifies how geographically specific infrastructure, purchasing frameworks, and manufacturing capabilities shape surveillance implementation and supplier strategies

Regional dynamics exert strong influence on surveillance priorities, supply chains, and the adoption curve for diagnostic technologies; this section synthesizes the distinct conditions and strategic implications across major geographies. In the Americas, established public health infrastructures and a concentration of reference laboratories support advanced adoption of sequencing and automated susceptibility testing, while procurement cycles and reimbursement frameworks shape supplier engagement models. Furthermore, regional interconnectivity in North and South America has prompted collaborative networks for outbreak detection and data sharing, which in turn influence how vendors position integrated hardware-software solutions and service offerings.

Across Europe, the Middle East and Africa, heterogeneity defines both challenge and opportunity. Well-resourced systems in parts of Western Europe have accelerated adoption of data-driven surveillance platforms and value digital interoperability, whereas resource-constrained settings in other parts of the region prioritize affordability, robustness, and ease of use. As a result, suppliers tailor portfolios to meet a wide spectrum of needs, often combining low-complexity, high-reliability assays with scalable software tools. In the Asia-Pacific region, diverse manufacturing capabilities, rapid technology diffusion, and significant investments in public health genomics create a dynamic marketplace for sequencing, real-time PCR, and automated AST solutions. Regional supply chain capabilities and domestic production policies also influence procurement choices, making local partnership strategies and flexible commercial models particularly effective for achieving deployment at scale

Actionable company-level insights highlighting how integrated platforms, supply resilience, and partnership models are redefining competitive advantage in surveillance solutions

Companies operating in the antimicrobial resistance surveillance space are evolving beyond single-product strategies toward integrated solution sets that combine hardware, reagents, informatics, and services, and this section distills the strategic moves that define competitive positioning. Leading diagnostic and life-science suppliers are investing in modular platforms that support both phenotypic and genotypic testing pathways, enabling clients to consolidate workflows and reduce complexity. At the same time, reagent specialists are developing validated assay panels that simplify regulatory compliance and accelerate deployment across heterogeneous laboratory environments. Strategic partnerships between instrument manufacturers and software developers are increasingly common, as interoperability and data analytics become critical differentiators for customers seeking end-to-end surveillance capabilities.

Additionally, many organizations are strengthening supply chain transparency and resilience through regional manufacturing, multi-sourcing strategies, and service contracts that bundle consumables with training and remote support. Sales and commercialization teams are adapting by offering flexible procurement models, including subscription and reagent-rental arrangements, which can lower adoption barriers for resource-constrained facilities. R&D priorities among companies reflect an emphasis on faster time-to-result, improved analytical sensitivity, and streamlined sample-to-answer workflows, while commercial strategies emphasize integrated clinical validation and health-economics evidence to support adoption. Together, these company-level trends signal a maturing market where technological breadth, supply reliability, and data integration increasingly determine competitive advantage

Practical, high-impact recommendations for executives and functional leaders to strengthen surveillance resilience, interoperability, and clinical utility across operations

Industry leaders must adopt focused, pragmatic strategies to translate surveillance intelligence into operational resilience and clinical impact, and this section outlines a set of high-impact recommendations tailored to senior executives and functional leaders. First, prioritize supplier diversification and contractual mechanisms that secure critical consumables and spare parts without locking organizations into single-source dependencies; building regional supplier relationships and embracing flexible procurement models can materially reduce operational risk. Second, invest in interoperable data architectures and validated analytics that connect laboratory outputs with clinical and public health systems; interoperability enables faster detection, centralized monitoring, and coordinated responses across institutional boundaries. Third, accelerate targeted automation and digital workflows that relieve skilled personnel from repetitive tasks while improving reproducibility and throughput; combine automation with competency development programs to maintain workforce depth.

Fourth, realign product and service portfolios around modular integration, ensuring that instruments, reagents, and software can be deployed in layered configurations that meet diverse end-user needs. Fifth, embed regulatory and quality assurance planning into product roadmaps to streamline approvals and enhance trust among clinical customers. Finally, foster collaborative models with public health agencies, academic centers, and industry partners to co-develop sentinel surveillance projects and pilot implementations; these collaborations generate operational evidence, validate real-world performance, and create pathways for scaled adoption. Implementing these recommendations requires disciplined governance, prioritized investment, and a focus on measurable outcomes tied to clinical utility and system resilience

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, expert validation, and cross-regional comparison to support robust conclusions

The research methodology underpinning this analysis blends qualitative and quantitative approaches to ensure robust, evidence-based conclusions while maintaining transparency about data sources and validation processes. Primary research included structured interviews with laboratory leaders, procurement specialists, clinical microbiologists, public health officials, and technology vendors to capture first-hand perspectives on operational challenges, procurement behaviors, and technology adoption barriers. These insights were supplemented by a comprehensive review of peer-reviewed literature, regulatory guidance, technical whitepapers, and published clinical validation studies that detail assay performance characteristics and workflow integration considerations.

To ensure analytical rigor, findings were triangulated across multiple sources and subjected to expert validation rounds, where independent subject-matter experts reviewed assumptions, interpreted technical trade-offs, and assessed the operational feasibility of recommended actions. The methodology also incorporated cross-regional comparisons to highlight contextual differences and to identify where localized strategies are necessary. Limitations include variability in reporting standards across institutions and the evolving nature of regulatory pathways for new diagnostic modalities, which were addressed through conservative interpretation of qualitative data and transparent documentation of data provenance. Overall, the methodological approach emphasizes reproducibility, stakeholder validation, and the translation of technical evidence into actionable strategic guidance

Conclusive synthesis emphasizing coordinated investment in technology, interoperability, and supply resilience to protect therapeutic efficacy and public health outcomes

In conclusion, antimicrobial resistance surveillance is transitioning from a collection of discrete laboratory activities into a coordinated, data-driven system that spans clinical care, public health, food safety, and environmental monitoring. Technological advances in rapid phenotypic testing, sequencing, and digital analytics are enabling richer surveillance signals and faster interventions, but realizing this potential requires intentional investment in interoperability, workforce capacity, and supply chain resilience. The confluence of policy changes, procurement pressures, and evolving commercial models means that organizations must balance near-term operational continuity with longer-term capability building.

The synthesis underscores the importance of modular solutions that can be adapted to diverse laboratory settings, the necessity of diversified supplier strategies in the face of trade and tariff disruption, and the strategic value of integrated software and service offerings that translate raw data into actionable insights. Leaders who proactively align procurement, technology adoption, and governance will be better positioned to detect emerging resistance trends, support antimicrobial stewardship programs, and protect patient outcomes. This conclusion is a call to action for coordinated effort across manufacturers, laboratories, policymakers, and funders to prioritize surveillance as a foundational public health asset

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel CRISPR-based diagnostic tools for rapid AMR detection in clinical settings
  • 5.2. Integration of artificial intelligence and machine learning for predictive antibiotic resistance modeling in surveillance networks
  • 5.3. Adoption of whole genome sequencing to map regional multidrug resistant bacterial transmission pathways
  • 5.4. Expansion of community wastewater surveillance programs to identify emerging resistance genes in urban populations
  • 5.5. Regulatory push for standardized global reporting frameworks to unify antimicrobial resistance data sharing protocols
  • 5.6. Growth of point-of-care molecular assays enabling decentralized AMR testing in resource-limited environments
  • 5.7. Strategic partnerships between pharmaceutical companies and academic institutions to accelerate novel antibiotic discovery targeting resistant pathogens
  • 5.8. Implementation of One Health initiatives linking human, animal, and environmental AMR surveillance data for holistic risk assessments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Surveillance Market, by Offering

  • 8.1. Consumables And Reagents
    • 8.1.1. Antibiotic Panels
    • 8.1.2. Culture Media
    • 8.1.3. PCR Kits
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Antimicrobial Resistance Surveillance Market, by Technology

  • 9.1. Automated AST Systems
  • 9.2. Manual AST
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Antimicrobial Resistance Surveillance Market, by Application

  • 10.1. Environmental Monitoring
  • 10.2. Epidemiological Surveillance
  • 10.3. Food Safety Testing
  • 10.4. Infection Control

11. Antimicrobial Resistance Surveillance Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Clinical Laboratories
  • 11.3. Hospital Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies
  • 11.5. Reference Laboratories

12. Antimicrobial Resistance Surveillance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antimicrobial Resistance Surveillance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Resistance Surveillance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific, Inc.
    • 15.3.2. F. Hoffmann-La Roche Ltd
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. bioMerieux SA
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Illumina, Inc.
    • 15.3.7. bio-Rad Laboratories, Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Merck KGaA
    • 15.3.10. Accelerate Diagnostics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTIMICROBIAL